New systemic therapies are urgently needed for triple-negative breast cancer tumors because hormonal therapies and HER2-targeted agents are ineffective. Nature Reviews Clinical Oncology
The US Food and Drug Administration rejected it as a chemopreventive agent for prostate cancer. Can dutasteride live up to its billing in another trial? Medscape Medical News
In this expert interview, Dr. Rajkumar discusses the latest data on the treatment of multiple myeloma as reported at the 2008 American Society of Hematology annual meeting. Medscape Hematology-Oncology
Cervical tissue samples that are too small are not appropriate to assess for p16 positivity; the use of the p16 assay on limited samples could lead to the overdiagnosis of endocervical cancer. Medscape Medical News
Dr. Maurie Markman reports on a phase 3 trial confirming that paclitaxel-carboplatin is equivalent and less toxic than paclitaxel-carboplatin-doxorubicin in metastatic endometrial cancer. Medscape Hematology-Oncology